trial

First Time in Human Study With GSK1018921

NCTId NCT00527020
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1 · Completed
Enrollment 27 (actual)
Sponsored by GlaxoSmithKline
Primary completion 2008-07-12
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1
Status
Completed
Enrollment
27 (actual)
Study type
Interventional
Allocation
Randomized
Model
Crossover
Masking
—
Start
2007-08-10
Primary completion
2008-07-12
Eligibility
ALL · 18 Years · 55 Years

Interventions & indications

Drugs
GSK1018921Nicotine Lozenges

Sponsors

GlaxoSmithKlineLead Sponsor

Sites

1 total
Berlin, Germany

Facts & assertions

4 sourced
Enrollment
27
Phase
PHASE1
Primary Completion Date
2008-07-12
Status
COMPLETED
relationships
The graph out of here
drug
GSK1018921
drug
Nicotine Lozenges
drug
lead_sponsor
GlaxoSmithKline
company
indication
Schizophrenia
indication
Schizophrenia
indication